Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial Posted on March 7, 2022 By Merck’s KEYTRUDA Demonstrated Significant Improvement in Distant Metastasis-Free Survival in Stage IIB and IIC Melanoma in KEYNOTE-716 Trial News
